Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria

  • M. E. Falagas
  • S. K. Kasiakou
  • D. P. Kofteridis
  • G. Roditakis
  • G. Samonis
Concise Article

DOI: 10.1007/s10096-006-0191-2

Cite this article as:
Falagas, M.E., Kasiakou, S.K., Kofteridis, D.P. et al. Eur J Clin Microbiol Infect Dis (2006) 25: 596. doi:10.1007/s10096-006-0191-2

Abstract

The prospective case series study presented here was conducted to assess the outcome of patients with infections caused by polymyxin-only-susceptible (POS) gram-negative bacteria managed with intravenous colistin. Between July 2003 and April 2005 a total of 27 patients were infected with a POS gram-negative bacterium and received intravenous colistin at a dose of 2 million international units (MIU) (160 mg or 66.7 mg colistin base) every 8 h for a mean (±SD) duration of 13.9 (±7.5) days. Nine patients had ventilator-associated pneumonia and received, in addition to the intravenous colistin therapy, 1 MIU (80 mg or 33.3 mg colistin base) aerosolized colistin every 12 h for a mean (±SD) duration of 13 (±6.5) days. The predominant pathogens were Pseudomonas aeruginosa (n=17) and Acinetobacter baumannii (n=12); in two patients both pathogens were isolated from one clinical specimen. In-hospital mortality and clinical response were 15% and 85%, respectively. Colistin-associated nephrotoxicity was observed in two of the 27 patients. POS gram-negative pathogens represent a major threat for hospitalized patients. Colistin appears to be an effective and safe treatment, even in patients with severe underlying diseases.

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • M. E. Falagas
    • 1
    • 2
    • 3
  • S. K. Kasiakou
    • 3
  • D. P. Kofteridis
    • 4
  • G. Roditakis
    • 4
  • G. Samonis
    • 4
  1. 1.Department of MedicineTufts University School of MedicineBostonUSA
  2. 2.Department of Medicine“Henry Dunant” HospitalAthensGreece
  3. 3.Alfa Institute of Biomedical Sciences (AIBS)AthensGreece
  4. 4.Department of Internal MedicineUniversity of Crete School of Medicine and University HospitalHeraklionGreece

Personalised recommendations